Bjørnar G.
- Country
- Norway
- Department
- Dpt of oncology
Research Overview
- Phase 3 Randomized Study of Sacituzumab Tirumotecan and Pembrolizumab Versus Physician's Choice in Triple-Negative Breast Cancer Post-Neoadjuvant Therapy
- Open-Label Extension Study on Long-Term Safety of Enzalutamide in Prostate Cancer Patients from Previous Clinical Trials
- Evaluation of Dose-Dense Cyclophosphamide in Patients with TP53 Mutated or Wild-Type Advanced Breast Cancer
Data & Insights
Has run more than one trial at 16 of 167 partner sites.
Specializations
Breast Cancer Research
This investigator specializes in the treatment of various forms of breast cancer, with particular emphasis on hormone receptor-positive HER2-negative breast cancer and triple-negative breast cancer.
- Endocrine Therapy Approaches
- Molecular Response Assessment
- Personalized Treatment Strategies
The investigator focuses on neoadjuvant therapeutic approaches and molecular marker identification for treatment response.
Molecular Oncology
Expertise in molecular biomarker research and personalized cancer treatment, including studies of TP53 mutations in breast cancer patients.
- Biomarker Analysis
- Treatment Response Prediction
- High-risk Cancer Management
Research interests include molecular markers of therapy response and resistance patterns in cancer treatment.
Prostate Cancer Studies
The investigator conducts research in prostate cancer treatment, with a focus on long-term therapeutic outcomes and clinical benefit assessment.
- Treatment Safety Evaluation
- Long-term Patient Monitoring
- Clinical Benefit Analysis
Specialized work includes evaluation of novel therapeutic agents and their long-term safety profiles.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.